Lots of discussion here, great.  Most stock prices are multiples of earnings and free cash flow.  Some investors may add future proven revenue stream to price.  RVX would be splitting its earnings with a partner, so stock price will be reduced, same as increasing issued stock.  Maybe I used the wrong term (dilution), please excuse.  Using a partner to fund the necessary FDA requirements to get to market will reduce future RVX earnings and pps.

My glass is more than half full.  Still believe in the science.  Funding to get to the market is most concerning.   We are so close to the finish.  Only way RVX stays alive is to slowly sell itself, borrow, or find a takeout with BP.  Borrowing does not seem to be an option with lenders.  No proven revenue stream. RVX will always be the father of 208.

A takeout gets more complicated with HL and Zenith. We should know more in two, three or four months.  DM has brought us to the gate, great job there.  Science will prevail.  HL will want to keep or have China rights, a package deal combined with Zenith does have many benefits for BP, but very complicated.  IMHO, sidebar with stock in the six figures.  In for the long run.